From Data to Trust, Post Marketing Results in the Syrian Context. 

In 2010, Ibn Al-Haytham led REST EXTRA, a post-marketing observational study evaluating the efficacy, safety, and tolerability of REVOSYL Extra in managing essential hypertension—not in theory, but in actual clinical practice across Syria.

Study Scope:

• Patients: 1614

• Participating Doctors: 102

• Setting: Diverse outpatient environments across the country

Efficacy Rating:

• 91.1% Controlled

• 8.9 % Uncontrolled

Tolerability Ratings:

• 75.8 % Excellent

•  20.1 % Good

• 2.4% Fair

• 1.7% Poor
  
   

This study didn’t just measure molecules—it measured lives impacted, trust earned, and clinical realities navigated.

At Ibn Al-Haytham, we believe that credibility isn’t claimed—it’s demonstrated through transparent data, regional relevance, and patient-first insights.